Aptevo Therapeutics Inc. (APVO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 15M 30M 45M Q4 '15: 33.6M Q1 '16: 30M Q2 '16: 33.1M Q3 '16: 29.4M Q4 '16: 29.8M Q1 '17: 23.9M Q2 '17: 17.3M Q3 '17: 20.6M Q4 '17: 14.7M Q1 '18: 16.6M Q2 '18: 19.9M Q3 '18: 19.5M Q4 '18: 23.1M Q1 '19: 26M Q2 '19: 26.6M Q3 '19: 29.7M Q4 '19: 32.4M Q1 '21: 6.7M Q2 '21: 9.4M Q3 '21: 11M Q4 '21: 12.3M Q1 '22: 13M Q2 '22: 9.9M Q3 '22: 6.8M Q4 '22: 3.1M Q4 '15 Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '21 Q4 '22

Gross Profit TTM

0 5M 10M 15M Q4 '18: 11.9M Q1 '19: 12.7M Q2 '19: 9.8M Q3 '19: 11.5M Q4 '19: 12.5M Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -134.9M Q4 '16: -130.9M Q1 '17: -130.1M Q2 '17: -131.9M Q3 '17: -51.7M Q4 '17: -53.9M Q1 '18: -55.3M Q2 '18: -53.1M Q3 '18: -54.9M Q4 '18: -51.7M Q1 '19: -49.6M Q2 '19: -50.1M Q3 '19: -49.4M Q4 '19: -43.7M Q1 '20: -39.9M Q2 '20: -33.8M Q3 '20: -28.6M Q4 '20: -27.5M Q1 '21: -26.8M Q2 '21: -25.7M Q3 '21: -24.2M Q4 '21: -21.4M Q1 '22: -20.1M Q2 '22: -22M Q3 '22: -25M Q4 '22: -28.6M Q1 '23: -30.8M Q2 '23: -31.4M Q3 '23: -30.2M Q4 '23: -28.9M Q1 '24: -28.1M Q2 '24: -26M Q3 '24: -24.6M Q4 '24: -24.6M Q1 '25: -24.1M Q2 '25: -24.3M Q3 '25: -26.7M Q4 '25: -26.3M Q1 '26: -26.7M Q2 '26: -26.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -115.4M Q4 '16: -112.4M Q1 '17: -109.5M Q2 '17: -107.8M Q3 '17: 1.8M Q4 '17: 7M Q1 '18: 3.1M Q2 '18: 1.1M Q3 '18: -49.3M Q4 '18: -53.7M Q1 '19: -51.9M Q2 '19: -52M Q3 '19: -46.4M Q4 '19: -40.4M Q1 '20: -25.5M Q2 '20: -19M Q3 '20: -18.9M Q4 '20: -17.8M Q1 '21: -27.9M Q2 '21: -29M Q3 '21: -29.2M Q4 '21: -28.5M Q1 '22: -28.9M Q2 '22: 7M Q3 '22: 6.4M Q4 '22: 8M Q1 '23: 18.5M Q2 '23: -17.5M Q3 '23: -16.2M Q4 '23: -17.4M Q1 '24: -27M Q2 '24: -25M Q3 '24: -23.7M Q4 '24: -24.1M Q1 '25: -23.7M Q2 '25: -24M Q3 '25: -26.5M Q4 '25: -26M Q1 '26: -26.3M Q2 '26: -26.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 7M 14M 21M Q4 '18: 11.2M Q1 '19: 13.3M Q2 '19: 16.7M Q3 '19: 18.3M Q4 '19: 19.9M Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '16: -37.9M Q4 '16: -36.9M Q1 '17: -34.8M Q2 '17: -31.3M Q3 '17: -32.8M Q4 '17: -41.6M Q1 '18: -46.5M Q2 '18: -50M Q3 '18: -59.6M Q4 '18: -51.4M Q1 '19: -48.3M Q2 '19: -48.2M Q3 '19: -44.6M Q4 '19: -42.4M Q1 '20: -39.7M Q2 '20: -28.5M Q3 '20: -28.3M Q4 '20: -29.3M Q1 '21: -25.6M Q2 '21: -26.1M Q3 '21: -23.9M Q4 '21: -21.7M Q1 '22: -19.3M Q2 '22: -17.3M Q3 '22: -19M Q4 '22: -21M Q1 '23: -11.3M Q2 '23: -13.1M Q3 '23: -12.4M Q4 '23: -11.7M Q1 '24: -22.9M Q2 '24: -24.3M Q3 '24: -23.3M Q4 '24: -23.8M Q1 '25: -23.7M Q2 '25: -24.6M Q3 '25: -26.1M Q4 '25: -25.6M Q1 '26: -27M Q2 '26: -25.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q2 '16: -50M Q3 '16: -40.3M Q4 '16: -39.4M Q1 '17: -37M Q2 '17: -32.8M Q3 '17: -34.5M Q4 '17: -43M Q1 '18: -47.6M Q2 '18: -51M Q3 '18: -60.8M Q4 '18: -52.4M Q1 '19: -48.9M Q2 '19: -48.7M Q3 '19: -44.8M Q4 '19: -42.5M Q4 '21: -22.4M Q3 '16 Q1 '17 Q3 '17 Q1 '18 Q3 '18 Q1 '19 Q3 '19 Q4 '21

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 8M 16M 24M Q3 '16: 20.2M Q1 '17: 20.8M Q2 '17: 21.3M Q3 '17: 21.7M Q1 '18: 22M Q2 '18: 22.6M Q3 '18: 22.7M Q2 '21: 4.5M Q3 '21: 4.9M Q1 '22: 4.9M Q2 '22: 5M Q3 '22: 5.1M Q1 '23: 159.6K Q2 '23: 147.3K Q3 '23: 285.9K Q1 '24: 18.6K Q2 '24: 4.8K Q3 '24: 14.3K Q1 '25: 4.1K Q2 '25: 41K Q3 '25: 4M Q1 '26: 1.1M Q2 '26: 1.2M Q1 '17 Q1 '18 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45000.00 -30000.00 -15000.00 0.00 15000.00 30000.00 45000.00 Q4 '15: -2.93 Q1 '16: -3.03 Q2 '16: -2.78 Q3 '16: -5.70 Q4 '16: -5.56 Q1 '17: -5.40 Q2 '17: -5.30 Q3 '17: 0.00 Q4 '17: 0.33 Q1 '18: 0.18 Q2 '18: 0.13 Q3 '18: -2.18 Q4 '18: -2.39 Q1 '19: -9.40 Q2 '19: -12.96 Q3 '19: -14.55 Q4 '19: -16.31 Q1 '20: -7.78 Q2 '20: -5.74 Q3 '20: -5.69 Q4 '20: -5.23 Q1 '21: -7.76 Q2 '21: -7.41 Q3 '21: -6.74 Q4 '21: -6.09 Q1 '22: -6.00 Q2 '22: 1.33 Q3 '22: 1.26 Q4 '22: 1.57 Q1 '23: 20.50 Q2 '23: -39.03 Q3 '23: -59.69 Q4 '23: -2319.34 Q1 '24: -2704.93 Q2 '24: -3887.94 Q3 '24: -4223.64 Q4 '24: -29713.50 Q1 '25: -30927.10 Q2 '25: -29841.43 Q3 '25: -29485.80 Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q4 '21 Q1 '23 Q2 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.